Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688767 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Hangzhou Biotest Biotech Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hangzhou Biotest Biotech Co Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hangzhou Biotest Biotech Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Hangzhou Biotest Biotech Co's Days Payable falls into.
Hangzhou Biotest Biotech Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hangzhou Biotest Biotech Co (SHSE:688767) has a Days Payable of 159.78 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Hangzhou Biotest Biotech Co and its competitors. This is 66% above median its historical median of 96.20. Over the past decade, Hangzhou Biotest Biotech Co's Days Payable has ranged from 64.57 to 122.23. According to the industry distribution chart, Hangzhou Biotest Biotech Co ranks #382 out of 701 companies in the Biotechnology industry, placing it in the top 54.5%.
Is Hangzhou Biotest Biotech Co's Days Payable too high?
Hangzhou Biotest Biotech Co's current Days Payable of 159.78 is 66% above median its 10-year median of 96.20. Over the past 10 years, this metric has ranged from a low of 64.57 to a high of 122.23. The Biotechnology industry median Days Payable is 112.84. Hangzhou Biotest Biotech Co's value of 159.78 is 41.6% above this industry median. Based on the distribution chart, Hangzhou Biotest Biotech Co ranks #382 out of 701 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Hangzhou Biotest Biotech Co has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hangzhou Biotest Biotech Co's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hangzhou Biotest Biotech Co ranks #382 out of 701 companies for Days Payable. This places Hangzhou Biotest Biotech Co in the lower half of its industry. The industry median Days Payable is 112.84. Hangzhou Biotest Biotech Co's value of 159.78 is 41.6% above this benchmark. Historically, Hangzhou Biotest Biotech Co's own Days Payable has ranged from 64.57 to 122.23 over the past decade. While the company's 10-year median is 96.20 vs. the industry median of 112.84, Hangzhou Biotest Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hangzhou Biotest Biotech Co's current Days Payable of 159.78 is 41.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Hangzhou Biotest Biotech Co and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hangzhou Biotest Biotech Co's current Days Payable is 159.78, which is 66% above median its own 10-year median of 96.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hangzhou Biotest Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Hangzhou Biotest Biotech Co (SHSE:688767) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥26.87, compared to a current price of ¥34.50 — trading 28.4% above its estimated fair value. The current Days Payable is 159.78, which is 66% above median its 10-year median of 96.20 and 41.6% above the Biotechnology industry median of 112.84. Hangzhou Biotest Biotech Co's overall GF Score™ is 71/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Hangzhou Biotest Biotech Co (SHSE:688767), the current Days Payable is 159.78 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hangzhou Biotest Biotech Co (SHSE:688767) Overvalued in 2026?
Based on GuruFocus' analysis, Hangzhou Biotest Biotech Co stock appears to be overvalued.
The current stock price of ¥34.50 is trading 28.4% above its estimated GF Value™ of ¥26.87.
GuruFocus considers Hangzhou Biotest Biotech Co to be Modestly Overvalued.
Key valuation signals for SHSE:688767:
Days Payable: 159.78 (66% above median its 10-year median of 96.20)
GF Value™: ¥26.87 vs. price of ¥34.50 (28.4% above fair value)
Industry Position: 41.6% above the Biotechnology median (#382 of 701)
No single metric tells the full story. See the SHSE:688767 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hangzhou Biotest Biotech Co Ltd is engaged in the research and development, manufacturing, sales and service of in vitro diagnostic reagents, raw materials and instruments.
71GF Score
Get the complete analysis for SHSE:688767
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688767 has been successfully added to your 
